Bernstein Confirms Neutral Rating on Fresenius Medical Care
Published
The investment bank Bernstein has reaffirmed its neutral rating on the shares of Fresenius Medical Care. Following its own research, the brokerage firm is maintaining its previous recommendation. This was reported by the financial portal MarketScreener.
Fresenius Medical Care is a German medical company based in Bad Homburg. The company specializes primarily in the treatment of kidney diseases and operates dialysis centers worldwide. Analysts such as Bernstein monitor companies like this closely, because their assessments help investors make purchasing decisions.
A neutral rating means that analysts recommend neither a clear buy nor a clear sell of the shares. They expect the share price to develop roughly in line with the market as a whole over the foreseeable future. Bernstein therefore currently sees no clear reason to change its assessment.
The report contains no further details about the research or the possible reasons behind the decision. Investors interested in the company should therefore also read the official quarterly reports and announcements from Fresenius Medical Care.
Sources: MarketScreener Deutschland
More Germany news
- Mercedes-Benz Halts Investment in German Plants and Weighs Closures
- Housing Benefit Cut Dropped: 1.3 Million Households Keep Wohngeld
- Align Technology unveils new innovations for Invisalign treatment
- Large Solar Park in Merbitz Feeds Electricity into the Grid
- Nvidia shares fall sharply: How safe is pension money?
- Telekom baut Rechenzentrum für Industrie und KI aus
- Autonomous Buses to Enter Everyday Life: TUM Leads New DZM Site
- Cigarettes from the EU Abroad: Duty-Free Allowance Not Dropping for Now